Clinical Trials
15 trialsNCT05028166 2026-05-08
Individual Patient Compassionate Use of Mirdametinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Available
NCT05511714 2026-04-24
Expanded Access [11C] Methionine PET Imaging
St. Jude Children's Research Hospital
Available
NCT01163383 2026-04-13
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
Available
NCT07497984 2026-03-27
ITM11 Expanded Access Program
ITM Solucin GmbH
Available
NCT03581240 2026-02-20
An Intermediate Expanded Use Trial of DFMO
Milton S. Hershey Medical Center
Available
NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT06872489 2025-07-23
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
Available
NCT01370330 2025-07-22
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
Available
NCT06743100 2025-04-02
18F-Floretyrosine Expanded Access Program
Telix Pharmaceuticals (Innovations) Pty Limited
Available
NCT06676891 2025-01-08
Expanded Access Program for GBM Subjects
Rznomics, Inc.
Available
NCT03015844 2024-07-05
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Northwell Health
Available
NCT05356312 2024-03-01
Glioblastoma and Individualized Therapies
Zentrum fur Humangenetik Tuebingen
Available
NCT01590680 2023-02-28
Expanded Access Protocol Using 131I-MIBG
Jubilant DraxImage Inc.
Available
NCT02146066 2016-02-26
DCVax-L EAP
Northwest Biotherapeutics
Available